{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05546580",
            "orgStudyIdInfo": {
                "id": "CL04-ORY-1001"
            },
            "organization": {
                "fullName": "Oryzon Genomics S.A.",
                "class": "INDUSTRY"
            },
            "briefTitle": "Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+)",
            "officialTitle": "An Escalation/Expansion, Open Label, Multicenter Study of Iadademstat and Gilteritinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+): The FRIDA Study",
            "acronym": "FRIDA",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "study-of-iadademstat-and-gilteritinib-in-patients-with-r-r-aml-with-fms-like-tyrosine-kinase-mutation-mut"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2022-11-14",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-11-30",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-11-30",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2022-09-15",
            "studyFirstSubmitQcDate": "2022-09-15",
            "studyFirstPostDateStruct": {
                "date": "2022-09-21",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-26",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-29",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Oryzon Genomics S.A.",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "Iadademstat is being studied as a treatment for subjects with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) with FMS-like tyrosine kinase mutation (FLT3 mut+). During the trial, iadademstat will be given in combination with gilteritinib, a drug that is already approved to treat patients with FLT3-mutated R/R AML.",
            "detailedDescription": "This is an escalation/expansion, open label, single arm, study to investigate the safety and the RP2D of the combination of iadademstat with gilteritinib in FLT3-mutated R/R AML.\n\nThis study consists of 2 parts. A dose finding part to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD) and emerging activity of iadademstat and gilteritinib combination, and to determine the pharmacologically-active dose (i.e., the minimum safe and biologically active dose) of iadademstat in combination with gilteritinib, and an expansion part at the specific dose/s selected to evaluate the activity of iadademstat in combination with gilteritinib in patients with FLT3-mutated R/R AML."
        },
        "conditionsModule": {
            "conditions": [
                "Acute Myeloid Leukemia, in Relapse",
                "Acute Myeloid Leukemia Refractory"
            ],
            "keywords": [
                "Acute Myeloid Leukemia, FLT3 mut"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "interventionModelDescription": "Escalation/extension open label study",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 50,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Active arm",
                    "type": "EXPERIMENTAL",
                    "description": "iadademstat and gilteritinib",
                    "interventionNames": [
                        "Drug: Iadademstat",
                        "Drug: Gilteritinib Oral Tablet"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Iadademstat",
                    "description": "iadademstat oral solution",
                    "armGroupLabels": [
                        "Active arm"
                    ],
                    "otherNames": [
                        "ORY-1001, RO7051790"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Gilteritinib Oral Tablet",
                    "description": "120 mg Gilteritinib",
                    "armGroupLabels": [
                        "Active arm"
                    ],
                    "otherNames": [
                        "XOSPATA\u00ae"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Adverse Events (AE)",
                    "description": "Number of participants with Adverse Events (AE) after treatment with iadademstat in combination with gilteritinib in patients with FLT3-mutated R/R AML.",
                    "timeFrame": "Up to 18 months"
                },
                {
                    "measure": "Laboratory value abnormalities and/or adverse events (AE)",
                    "description": "Number of participants with laboratory value abnormalities and/or Adverse Events (AE) after treatment with iadademstat in combination with gilteritinib in patients with FLT3-mutated R/R AML.",
                    "timeFrame": "Up to 18 months"
                },
                {
                    "measure": "Vital sign abnormalities and/or adverse events (AEs)",
                    "description": "Number of participants with vital signs abnormalities and/or Adverse Events (AE) after treatment with iadademstat in combination with gilteritinib in patients with FLT3-mutated R/R AML.",
                    "timeFrame": "Up to 18 months"
                },
                {
                    "measure": "Routine 12-lead electrocardiogram (ECG) abnormalities and/or Adverse Events (AEs)",
                    "description": "Number of participants with Routine 12-lead electrocardiogram (ECG )abnormalities and/or Adverse Events (AE) after treatment with iadademstat in combination with gilteritinib in patients with FLT3-mutated R/R AML.",
                    "timeFrame": "Up to 18 months"
                },
                {
                    "measure": "Recommend Phase 2 dose (RP2D)",
                    "description": "Determine the recommended Phase 2 dose (RP2D) of iadademstat in combination with gilteritinib in patients with FLT3-mutated R/R",
                    "timeFrame": "Up to 18 months"
                },
                {
                    "measure": "iadademstat tmax",
                    "description": "Measurement of the time it takes for iadademstat to reach the maximum concentration (Cmax) in blood.",
                    "timeFrame": "Up to 26 days"
                },
                {
                    "measure": "Iadademstat Cmax",
                    "description": "Measurement of the highest concentration of iadademstat in the blood after a dose is given.",
                    "timeFrame": "Up to 26 days"
                },
                {
                    "measure": "iadademstat Cmin",
                    "description": "Measurement of the lowest concentration of iadademstat in the blood, after a dose is given.",
                    "timeFrame": "Up to 26 days"
                },
                {
                    "measure": "iadademstat AUC",
                    "description": "Measurement of how much iadadmestat reaches a person's bloodstream in a given period of time after a dose is given.",
                    "timeFrame": "Up to 26 days"
                },
                {
                    "measure": "iadademstat Target Engagement (TE)",
                    "description": "Percent of drug covalently bound to LSD1 molecule",
                    "timeFrame": "Up to 26 days"
                },
                {
                    "measure": "OR rate",
                    "description": "Proportion of patients achieving complete remission (CR), CR with incomplete hematologic recovery (CRi), and partial remission (PR).",
                    "timeFrame": "Up to 18 months"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Overall Survival (OS)",
                    "description": "Time from start of treatment to the time of death from any cause.",
                    "timeFrame": "Up to 24 months"
                },
                {
                    "measure": "Event-Free-Survival (EFS)",
                    "description": "Time from start of treatment to the date of failure to achieve CR or CRi, relapse from CR/CRi, or death from any cause, whichever occurs first.",
                    "timeFrame": "Up to 18 months"
                },
                {
                    "measure": "Overall response rate",
                    "description": "Percentage of patients with complete remission (CR), CR with incomplete blood count recovery (CRi), or PR.",
                    "timeFrame": "Up to 6 months"
                },
                {
                    "measure": "Time to Response (TTR)",
                    "description": "Time from the date of initial dosing at RP2D/expansion dose to first documentation of either a type of CR or Partial Response (PR).",
                    "timeFrame": "Up to 6 months"
                },
                {
                    "measure": "Duration of Remission (DoR)",
                    "description": "Time from the date of first documentation of any type of remission to the date of first documentation of progression of remission for remitters",
                    "timeFrame": "Up to 18 months"
                },
                {
                    "measure": "Transfusion independence rate",
                    "description": "A patient is defined as red blood cell (RBC) and/or platelet-transfusion independent if he/she receives no RBC and/or platelet transfusions for a period of at least 8 weeks. Rate of transfusion independence is the percentage of patients who become RBC and/or platelet transfusion independent (from the number of patients transfusion dependent at baseline).",
                    "timeFrame": "Up to 18 months"
                },
                {
                    "measure": "Transplantation Rate Time Frame",
                    "description": "Percentage of patients undergoing Hematopoietic Stem Cell Transplantation (HSCT) during the study period.",
                    "timeFrame": "Up to 18 months"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Main Inclusion Criteria:\n\n* Diagnosis of primary AML or AML with myelodysplasia-related changes (AML-MRC)\n* Patient is in first or second relapse or has refractory disease. Patients must have had histologic verification of AML at the original diagnosis.\n* Patient must be positive for the following FLT3 mutations in bone marrow or PB: FLT3 internal tandem duplication (ITD), FLT3 tyrosine kinase domain (TKD) D835 or I836 or FLT3-ITD and specified FLT3-TKD.\n* ECOG performance status 0-2\n* Life expectancy of at least 3 months in the opinion of the investigator.\n* Normal hepatic and renal function.\n* Patient is able to swallow oral medications.\n* Female patients are postmenopausal, documented as surgically sterile, use two methods of contraception or practice true abstinence and have a negative urine pregnancy test at screening.\n* Male patients even if surgically sterilized agree to practice true abstinence or use highly effective barrier contraception.\n\nMain Exclusion Criteria:\n\n* Diagnosis of acute promyelocytic leukemia.\n* Known BCR-ABL-positive leukemia.\n* AML secondary to prior chemotherapy for other neoplasms (except for MDS).\n* AML that has relapsed after or is refractory to more than 2 lines of therapy.\n* Clinically active central nervous system leukemia or prior history of NCI CTCAE Grade \u2265 3 drug-related CNS toxicity.\n* Major surgery or radiation therapy within 4 weeks prior to the first study dose.\n* Prior treatment with iadademstat is not allowed. Treatment with any other agents with KDM1A/LSD1 inhibitory activity is only allowed if treatment finalized at least 3 weeks prior to first dose on study. Previous treatment with FLT3 inhibitors is allowed in the following cases: midostaurin and sorafenib are allowed when used in first-line therapy regimen as part of induction, consolidation and/or maintenance: quizartinib and gilteritinib are allowed when used in first-line therapy regimen, as part of induction, consolidation and/or maintenance, ONLY if patients were not refractory to the drugs or if responding, relapse did not occur while on these drugs.\n* Patients not eligible to receive gilteritinib per label.\n* Prior treatment with 3 or more lines of AML therapy.\n* Treatment with any investigational products within 3 weeks prior to first dose of study treatment.\n* Uncontrolled hypertension or poorly controlled diabetes.\n* Evidence of active uncontrolled viral, bacterial, or systemic fungal infection.\n* Pregnant or lactating women.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "M\u00f3nica Reale-Vidal, MD",
                    "role": "CONTACT",
                    "phone": "+34 935151313",
                    "email": "FRIDA_queries@oryzon.com"
                },
                {
                    "name": "Sonia Guti\u00e9rrez, MSc",
                    "role": "CONTACT",
                    "phone": "+34 935151313",
                    "email": "FRIDA_queries@oryzon.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "M\u00f3nica Reale-Vidal, MD",
                    "affiliation": "Oryzon Genomics",
                    "role": "STUDY_CHAIR"
                }
            ],
            "locations": [
                {
                    "facility": "Banner MD Anderson Cancer Center",
                    "status": "RECRUITING",
                    "city": "Gilbert",
                    "state": "Arizona",
                    "zip": "85234",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Rajneesh Nath, MD",
                            "role": "CONTACT",
                            "phone": "+34 935151313",
                            "email": "FRIDA_queries@oryzon.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 33.35283,
                        "lon": -111.78903
                    }
                },
                {
                    "facility": "The University of Arizona Cancer Center - North Campus",
                    "status": "RECRUITING",
                    "city": "Tucson",
                    "state": "Arizona",
                    "zip": "85724-5024",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Sharad Khurana, MD, MSc",
                            "role": "CONTACT",
                            "phone": "+34935151313",
                            "email": "FRIDA_queries@oryzon.com"
                        },
                        {
                            "name": "Sharad Khurana, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 32.22174,
                        "lon": -110.92648
                    }
                },
                {
                    "facility": "Sylvester Comprehensive Cancer Center",
                    "status": "RECRUITING",
                    "city": "Miami",
                    "state": "Florida",
                    "zip": "33136",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Sangeetha Venugopal, MD",
                            "role": "CONTACT",
                            "phone": "+34935151313",
                            "email": "FRIDA_queries@oryzon.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 25.77427,
                        "lon": -80.19366
                    }
                },
                {
                    "facility": "Miami Cancer Institute",
                    "status": "RECRUITING",
                    "city": "Miami",
                    "state": "Florida",
                    "zip": "33176",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Guenther Koehne, MD, PhD",
                            "role": "CONTACT",
                            "phone": "+34 935151313",
                            "email": "FRIDA_queries@oryzon.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 25.77427,
                        "lon": -80.19366
                    }
                },
                {
                    "facility": "The John Hopkins University School of Medicine",
                    "status": "RECRUITING",
                    "city": "Baltimore",
                    "state": "Maryland",
                    "zip": "21287-0013",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Alexander J Ambiender, MD",
                            "role": "CONTACT",
                            "phone": "+34 935151313",
                            "email": "FRIDA_queries@oryzon.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.29038,
                        "lon": -76.61219
                    }
                },
                {
                    "facility": "Massachusetts General Hospital (MGH)",
                    "status": "RECRUITING",
                    "city": "Boston",
                    "state": "Massachusetts",
                    "zip": "02114",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Amir Fathi, MD",
                            "role": "CONTACT",
                            "phone": "+34935151313",
                            "email": "FRIDA_queries@oryzon.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 42.35843,
                        "lon": -71.05977
                    }
                },
                {
                    "facility": "Rutgers, The State University",
                    "status": "RECRUITING",
                    "city": "Piscataway",
                    "state": "New Jersey",
                    "zip": "08854",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Neil D Palmisiano, MD, MS",
                            "role": "CONTACT",
                            "phone": "+34 935151313",
                            "email": "FRIDA_queries@oryzon.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.49927,
                        "lon": -74.39904
                    }
                },
                {
                    "facility": "Icahn School of Medicine at Mount Sinai and Mount Sinai Hospital",
                    "status": "RECRUITING",
                    "city": "New York",
                    "state": "New York",
                    "zip": "10029",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Jonathan Feld, MD",
                            "role": "CONTACT",
                            "phone": "+34935151313",
                            "email": "FRIDA_queries@oryzon.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.71427,
                        "lon": -74.00597
                    }
                },
                {
                    "facility": "Duke University Medical Center",
                    "status": "RECRUITING",
                    "city": "Durham",
                    "state": "North Carolina",
                    "zip": "27705",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Harry P Erba, MD",
                            "role": "CONTACT",
                            "phone": "+34935151313",
                            "email": "FRIDA_queries@oryzon.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 35.99403,
                        "lon": -78.89862
                    }
                },
                {
                    "facility": "Oregon Health & Science University",
                    "status": "RECRUITING",
                    "city": "Portland",
                    "state": "Oregon",
                    "zip": "97239",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Theodore P Braun, MD PhD",
                            "role": "CONTACT",
                            "phone": "+34 935151313",
                            "email": "FRIDA_queries@oryzon.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 45.52345,
                        "lon": -122.67621
                    }
                },
                {
                    "facility": "Sarah Cannon Research Institute, LLC",
                    "status": "RECRUITING",
                    "city": "Nashville",
                    "state": "Tennessee",
                    "zip": "37203",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Stephen Strickland, MD",
                            "role": "CONTACT",
                            "phone": "+34935151313",
                            "email": "FRIDA_queries@oryzon.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 36.16589,
                        "lon": -86.78444
                    }
                },
                {
                    "facility": "West Virginia University",
                    "status": "RECRUITING",
                    "city": "Morgantown",
                    "state": "West Virginia",
                    "zip": "26506",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Konstantinos Sdrimas, MD",
                            "role": "CONTACT",
                            "phone": "+34935151313",
                            "email": "FRIDA_queries@oryzon.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.62953,
                        "lon": -79.9559
                    }
                },
                {
                    "facility": "Froedtert Hospital & The Medical College of Wisconsin",
                    "status": "RECRUITING",
                    "city": "Milwaukee",
                    "state": "Wisconsin",
                    "zip": "53226",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Guru SG Murthy, MD",
                            "role": "CONTACT",
                            "phone": "+34935151313",
                            "email": "FRIDA_queries@oryzon.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 43.0389,
                        "lon": -87.90647
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000007938",
                    "term": "Leukemia"
                },
                {
                    "id": "D000007951",
                    "term": "Leukemia, Myeloid"
                },
                {
                    "id": "D000015470",
                    "term": "Leukemia, Myeloid, Acute"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009370",
                    "term": "Neoplasms by Histologic Type"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000006402",
                    "term": "Hematologic Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M10945",
                    "name": "Leukemia",
                    "asFound": "Leukemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10955",
                    "name": "Leukemia, Myeloid",
                    "asFound": "Myeloid Leukemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "M18127",
                    "name": "Leukemia, Myeloid, Acute",
                    "asFound": "Acute Myeloid Leukemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12315",
                    "name": "Neoplasms by Histologic Type",
                    "relevance": "LOW"
                },
                {
                    "id": "M9490",
                    "name": "Hematologic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "T3995",
                    "name": "Myeloid Leukemia",
                    "asFound": "Myeloid Leukemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "T182",
                    "name": "Acute Myeloid Leukemia",
                    "asFound": "Acute Myeloid Leukemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "T188",
                    "name": "Acute Non Lymphoblastic Leukemia",
                    "asFound": "Acute Myeloid Leukemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "T170",
                    "name": "Acute Graft Versus Host Disease",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC15",
                    "name": "Blood and Lymph Conditions"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "C000609080",
                    "term": "Gilteritinib"
                }
            ],
            "ancestors": [
                {
                    "id": "D000092004",
                    "term": "Tyrosine Kinase Inhibitors"
                },
                {
                    "id": "D000047428",
                    "term": "Protein Kinase Inhibitors"
                },
                {
                    "id": "D000004791",
                    "term": "Enzyme Inhibitors"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M21860",
                    "name": "Pharmaceutical Solutions",
                    "relevance": "LOW"
                },
                {
                    "id": "M58265",
                    "name": "Gilteritinib",
                    "asFound": "Recorder",
                    "relevance": "HIGH"
                },
                {
                    "id": "M2889",
                    "name": "Tyrosine Kinase Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M25820",
                    "name": "Protein Kinase Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M7951",
                    "name": "Enzyme Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "T22",
                    "name": "Tyrosine",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "PhSol",
                    "name": "Pharmaceutical Solutions"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "AA",
                    "name": "Amino Acids"
                }
            ]
        }
    },
    "hasResults": false
}